

Client: ARUP Example Report Only
500 Chipeta Way
Salt Lake City, UT 84108
UNITED STATES

Physician: ARUP, ARUP

Patient: Patient, Example

DOB

Sex: Unknown

Patient Identifiers: 32942

Visit Number (FIN): 33252

Collection Date: 1/26/2023 14:38

Fragile X (FMR1) with Reflex to Methylation Analysis, Fetal

ARUP test code 2009034

Fragile X Fetal Specimen	Amniocytes
Fragile X Allele 1	5 CGG repeats
Fragile X Allele 2	Not Applicable CGG repeats
Fragile X Methylation Pattern	Normal
Fragile X Interpretation, Fetal	See Note

One FMR1 allele with a CGG repeat size in the normal range was detected; therefore, this fetus is predicted to be neither affected with nor a carrier of fragile X syndrome (FXS). This test does not detect rare FMR1 variants causing less than 1% of FXS.

Methylation pattern is normal for gender.

This result has been reviewed and approved by Rong Mao, M.D.

BACKGROUND INFORMATION: Fragile X (FMR1) with Reflex to Methylation Analysis, Fetal
CHARACTERISTICS OF FRAGILE X SYNDROME (FXS): Affected males have moderate intellectual disability, hyperactivity, perseverative speech, social anxiety, poor eye contact, hand flapping or biting, autism spectrum disorders and connective tissue anomalies in males. Females are usually less severely affected than males.

CHARACTERISTICS OF FRAGILE X TREMOR ATAXIA SYNDROME (FXTAS): Onset of progressive ataxia and intention tremor typically after the fourth decade of life. Females also have a 21 percent risk for primary ovarian insufficiency. Incidence of FXS: 1 in 4,000 Caucasian males and 1 in 8,000 Caucasian females.

INHERITANCE: X-linked.

PENETRANCE OF FXS: Complete in males; 50 percent in females.

PENETRANCE OF FXTAS: 47 percent in males and 17 percent in females >50 years of age.

CAUSE: Expansion of the FMR1 gene CGG triplet repeat.

Full mutation: typically >200 CGG repeats (methylated).

Premutation: 55 to approx 200 CGG repeats (unmethylated).

Intermediate: 45-54 CGG repeats (unmethylated).

Normal: 5-44 CGG repeats (unmethylated).

CLINICAL SENSITIVITY: 99 percent.

METHODOLOGY: Triplet repeat-primed polymerase chain reaction (PCR) followed by size analysis using capillary electrophoresis. Methylation-specific PCR analysis is performed for CGG repeat

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com
500 Chipeta Way, Salt Lake City, UT 84108-1221
Jonathan R. Genzen, MD, PhD, Laboratory Director

Patient: Patient, Example

ARUP Accession: 23-026-116622

Patient Identifiers: 32942

Visit Number (FIN): 33252

Page 1 of 2 | Printed: 2/8/2023 12:33:11 PM

lengths of 55 or greater to distinguish between premutation and full mutation alleles.
ANALYTICAL SENSITIVITY AND SPECIFICITY: 99 percent; estimated precision of sizing for intermediate and premutation alleles is within 2-3 CGG repeats.
LIMITATIONS: Methylation patterns may not be fully established in early gestation; thus, diagnostic testing on chorionic villus samples is not recommended. Diagnostic errors can occur due to rare sequence variations. Rare FMR1 variants unrelated to trinucleotide expansion will not be detected. A specific CGG repeat size estimate is not provided for full mutation alleles. AGG trinucleotide interruptions within the FMR1 CGG repeat tract are not assessed.

PHENOTYPE	NUMBER OF CGG REPEATS
Unaffected	<45
Intermediate	45-54
Premutation	55-200
Affected	>200

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Counseling and informed consent are recommended for genetic testing. Consent forms are available online.

Maternal Contamination Study Fetal Spec

Fetal Cells

Single fetal genotype present; no maternal cells present. Fetal and maternal samples were tested using STR markers to rule out maternal cell contamination.

Maternal Contam Study, Maternal Spec

whole Blood

VERIFIED/REPORTED DATES

Procedure	Accession	Collected	Received	Verified/Reported
Fragile X Fetal Specimen	23-026-116622	1/26/2023 2:38:00 PM	1/26/2023 2:39:08 PM	2/7/2023 2:07:00 PM
Fragile X Allele 1	23-026-116622	1/26/2023 2:38:00 PM	1/26/2023 2:39:08 PM	2/7/2023 2:07:00 PM
Fragile X Allele 2	23-026-116622	1/26/2023 2:38:00 PM	1/26/2023 2:39:08 PM	2/7/2023 2:07:00 PM
Fragile X Methylation Pattern	23-026-116622	1/26/2023 2:38:00 PM	1/26/2023 2:39:08 PM	2/7/2023 2:07:00 PM
Fragile X Interpretation, Fetal	23-026-116622	1/26/2023 2:38:00 PM	1/26/2023 2:39:08 PM	2/7/2023 2:07:00 PM
Maternal Contamination Study Fetal Spec	23-026-116622	1/26/2023 2:38:00 PM	1/26/2023 2:39:08 PM	2/7/2023 2:07:00 PM
Maternal Contam Study, Maternal Spec	23-026-116622	1/26/2023 2:38:00 PM	1/26/2023 2:39:08 PM	2/7/2023 2:07:00 PM

END OF CHART

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com
500 Chipeta Way, Salt Lake City, UT 84108-1221
Jonathan R. Genzen, MD, PhD, Laboratory Director

Patient: Patient, Example
ARUP Accession: 23-026-116622
Patient Identifiers: 32942
Visit Number (FIN): 33252
Page 2 of 2 | Printed: 2/8/2023 12:33:11 PM